Edgewise Therapeutics (EWTX) Cash from Financing Activities (2020 - 2026)

Edgewise Therapeutics has reported Cash from Financing Activities for 7 years, with the latest figure at $12.2 million in Q1 2026.

• Quarterly Cash from Financing Activities rose 447.59% year-over-year to $12.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $206.0 million (up 1880.56% YoY) and the FY2025 annual result came in at $196.1 million, down 21.33% from the prior year.
• Cash from Financing Activities grew to $12.2 million in Q1 2026 per EWTX's latest filing, from $4.0 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $241.1 million in Q1 2024 and troughed at -$303000.0 in Q4 2022.
• A 5-year average of $37.7 million and a median of $2.2 million in 2025 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2022 and 2024: Cash from Financing Activities sank 203.41% in 2022, then soared 1147866.67% in 2024.
• Over 5 years, Cash from Financing Activities stood at -$303000.0 in 2022, then surged by 17587.46% to $53.0 million in 2023, then slumped by 94.54% to $2.9 million in 2024, then surged by 37.31% to $4.0 million in 2025, then surged by 206.24% to $12.2 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $12.2 million, $4.0 million, and $1.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.